{"doi":"10.1016/s0959-8049(11)70916-9","title":"1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)","abstract":null,"journal":"European Journal of Cancer","year":2011,"id":611071,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1571368,"name":"S.L. De Haas","orcid":null,"position":1,"is_corresponding":false},{"id":1571369,"name":"G. Romieu","orcid":null,"position":2,"is_corresponding":false},{"id":392067,"name":"A. Chan","orcid":"0000-0001-6913-6764","position":3,"is_corresponding":false},{"id":1571370,"name":"L. Dirix","orcid":null,"position":4,"is_corresponding":false},{"id":947990,"name":"J. Cortes","orcid":"0000-0002-7843-8470","position":5,"is_corresponding":false},{"id":1571371,"name":"P.R. Delmar","orcid":null,"position":6,"is_corresponding":false},{"id":1571372,"name":"S.J. Scherer","orcid":null,"position":7,"is_corresponding":false},{"id":1571367,"name":"D.W. Miles","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)","abstract":null,"is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W1999702412","authors":[],"funders":[],"total_grants":0,"fwci":0.7034,"citation_percentile":0.71031359,"influential_citations":0,"citation_trend":[{"year":2012,"count":2},{"year":2013,"count":3}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0959804911709169?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0959804911709169?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/s0959-8049(11)70916-9","host_type":"journal"}],"fields_of_study":["Cancer Treatment and Pharmacology","HER2/EGFR in Cancer Research","Advanced Breast Cancer Therapies","Medicine"],"mesh_terms":[],"keywords":["Metastatic breast cancer","Docetaxel","Medicine","Oncology","HER2 negative","Bevacizumab","Internal medicine","Breast cancer","Cancer","Chemotherapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T15:11:20.854767Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}